The U.S. Food and Drug Administration has approved Synjardy (empagliflozin and metformin hydrochloride) tablets to treat adults with type 2 diabetes. The drug is manufacutured by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company.
Synjardy is the third product containing empagliflozin to be approved by the FDA, following Jardiance (empagliflozin) and Glyxambi (empagliflozin/linagliptin).
Empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor, removes excess glucose through the urine by blocking glucose re-absorption in the kidney. Metformin, a commonly prescribed initial treatment for T2D, lowers glucose production by the liver and its absorption in the intestine.